How Much Water Is Safe to Drink Each Day with ADPKD?
At a Glance
There is no single daily water goal for everyone with ADPKD. People not taking tolvaptan may need an individualized plan, while those taking it should keep water available and drink to thirst; high fluid intake can be unsafe.
In this answer
4 sections
For people with ADPKD who are not taking tolvaptan, there is no single universal “liters-per-day” rule. Some research trials have aimed for 2.5 to 3 liters of total daily fluid (which includes water from both food and beverages), but the exact amount must be personalized by a nephrologist [1].
For patients taking tolvaptan, fluid needs are much higher because the medication causes massive water loss. However, you should never force a fixed predetermined volume of water. Instead, your doctor will provide a personalized plan, which usually involves keeping water available at all times and drinking to thirst [2].
In both cases, drinking large amounts of fluid is not safe for everyone and depends heavily on your specific kidney function and other health conditions [3].
The Biology: Why Hydration Matters
To understand why water is so heavily discussed in ADPKD, it helps to look at a specific hormone cascade in the body:
- Vasopressin release: When you do not consume enough fluid, your blood becomes more concentrated (a state called higher osmolality). The brain senses this and releases a hormone called vasopressin to tell your kidneys to hold onto water [4].
- cAMP production: Vasopressin binds to receptors in the kidneys, triggering a rise in an intracellular molecule called cAMP [5].
- Cyst growth: In ADPKD, high levels of cAMP promote cyst-cell growth and fluid secretion, causing the cysts to expand [6].
Drinking water keeps your blood dilute. This suppresses the release of vasopressin, which in turn lowers cAMP [4] [6]. However, it is important to note that a major 3-year randomized trial of prescribed high water intake did not demonstrate a significant slowing of kidney-volume growth or kidney-function decline over its study period [7]. High water intake has not been established as a substitute for tolvaptan or other medical management [7].
Fluid Guidelines for People Not Taking Tolvaptan
If you are not on tolvaptan, the goal of hydration in research settings is to lower urine concentration, not simply to hit a flat 3-liter goal [7].
- Individualized Targets: Achieving the dilute urine seen in trials often requires a high daily fluid intake, but this must be personalized to your body [1].
- Kidney Function Matters: This strategy is generally only considered for patients with preserved kidney function. If your kidney function (measured by eGFR, or estimated glomerular filtration rate) is significantly reduced, or if you have heart failure or swelling (edema), pushing high fluids can be dangerous and lead to fluid overload [3]. Never start a high-fluid plan based on your eGFR alone without consulting your doctor.
Fluid Guidelines for Patients on Tolvaptan
Tolvaptan is a selective V2-receptor antagonist used to slow kidney decline in certain adults at risk for rapidly progressing ADPKD [8].
- Replacing Fluid Loss: Tolvaptan causes aquaresis (massive loss of free water in the urine). While some patients may excrete 5 to 6 liters of urine a day, this varies greatly based on dose, diet, and the individual [9].
- Drink to Thirst: Because of the high urine output, you must keep water available day and night to avoid dehydration, low blood pressure, or acute kidney injury [10].
- Do Not Force Fluids: While you must replace lost fluids, drinking excessively beyond your thirst can cause hyponatremia (dangerously low blood sodium) [11]. Follow your prescriber’s specific instructions.
- Liver Safety: Tolvaptan requires strict monitoring for liver toxicity. You will need regular scheduled blood tests, and you should contact your doctor immediately if you experience jaundice (yellowing of skin/eyes), dark urine, or persistent nausea [12].
Tips for Safely Managing Hydration
Managing a large fluid intake and frequent urination can be exhausting and disruptive to daily life. Safely managing your hydration requires a practical strategy:
- Spread it out: Sip water continuously throughout the day. Do not chug large amounts at once, which increases the risk of hyponatremia [13].
- Dietary Support: Working with a renal dietitian to moderately lower your sodium (salt) intake can be beneficial for general ADPKD and blood pressure management [14]. However, do not severely restrict protein without medical supervision, as this can lead to poor nutrition.
- Do not chase clear urine: Persistently clear urine is not a reliable safety target and could indicate overhydration. Do not use home specific-gravity tests to change your water intake unless explicitly directed by your doctor [13].
- Have a Sick-Day Plan: If you get a stomach bug, fever, vomiting, or diarrhea and cannot keep fluids down, your risk of severe dehydration skyrockets, especially on tolvaptan. You must have a pre-arranged plan with your doctor on when to temporarily stop your medication and when to seek urgent medical care [15] [12]. Seek immediate help for fainting, severe dizziness, new confusion, marked weakness, or severely reduced urine output.
Common questions in this guide
What is a typical daily fluid amount for someone with ADPKD?
How should I drink water if I take tolvaptan?
Can drinking more water slow the growth of ADPKD cysts?
When could drinking a lot of water be unsafe with ADPKD?
What should I do if I vomit or have diarrhea while taking tolvaptan?
What monitoring does tolvaptan require?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my eGFR, heart health, and blood sodium levels, what is my specific, individualized daily fluid target?
- 2.If I am prescribed tolvaptan, what are the exact symptoms that should prompt me to call you or go to the emergency room?
- 3.Can we create a 'sick-day plan' so I know exactly what to do with my fluids and medications if I get a stomach bug and cannot keep water down?
- 4.What is my schedule for the required liver blood tests while taking tolvaptan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (15)
- 1
Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
Amro OW, Paulus JK, Noubary F, Perrone RD
American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(6)):882-891 doi:10.1053/j.ajkd.2016.07.023.
PMID: 27663039 - 2
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ, van Gastel MDA, Boertien WE, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2019; (73(3)):354-362 doi:10.1053/j.ajkd.2018.09.016.
PMID: 30578153 - 3
Nutritional therapy in autosomal dominant polycystic kidney disease.
Di Iorio BR, Cupisti A, D'Alessandro C, et al.
Journal of nephrology 2018; (31(5)):635-643 doi:10.1007/s40620-018-0470-x.
PMID: 29344814 - 4
Polycystic Kidney Disease and the Vasopressin Pathway.
van Gastel MDA, Torres VE
Annals of nutrition & metabolism 2017; (70 Suppl 1()):43-50 doi:10.1159/000463063.
PMID: 28614813 - 5
Vasopressin and disruption of calcium signalling in polycystic kidney disease.
Chebib FT, Sussman CR, Wang X, et al.
Nature reviews. Nephrology 2015; (11(8)):451-64 doi:10.1038/nrneph.2015.39.
PMID: 25870007 - 6
β3 adrenergic receptor as potential therapeutic target in ADPKD.
Schena G, Carmosino M, Chiurlia S, et al.
Physiological reports 2021; (9(20)):e15058 doi:10.14814/phy2.15058.
PMID: 34676684 - 7
Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.
Rangan GK, Wong ATY, Munt A, et al.
NEJM evidence 2022; (1(1)):EVIDoa2100021 doi:10.1056/EVIDoa2100021.
PMID: 38319283 - 8
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
Devuyst O, Chapman AB, Gansevoort RT, et al.
Journal of the American Society of Nephrology : JASN 2017; (28(5)):1592-1602 doi:10.1681/ASN.2016040448.
PMID: 27920153 - 9
Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
Côté G, Asselin-Thompstone L, Mac-Way F, et al.
International urology and nephrology 2020; (52(2)):343-349 doi:10.1007/s11255-020-02384-3.
PMID: 32008201 - 10
Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
Akihisa T, Kataoka H, Makabe S, et al.
Clinical and experimental nephrology 2022; (26(6)):540-551 doi:10.1007/s10157-022-02192-2.
PMID: 35165806 - 11
Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.
Yamazaki M, Kawano H, Miyoshi M, et al.
International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25042088.
PMID: 38396765 - 12
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT, Perrone RD, Chapman AB, et al.
Journal of the American Society of Nephrology : JASN 2018; (29(10)):2458-2470 doi:10.1681/ASN.2018060590.
PMID: 30228150 - 13
High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.
El-Damanawi R, Lee M, Harris T, et al.
QJM : monthly journal of the Association of Physicians 2020; (113(4)):258-265 doi:10.1093/qjmed/hcz278.
PMID: 31665476 - 14
The PKD Daily: Development and Content Validation of a Hybrid Diary for Tracking Urinary Events in Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
O'Connor M, Broderick L, Waldman LT, et al.
Advances in therapy 2026; (43(5)):2054-2070 doi:10.1007/s12325-026-03528-0.
PMID: 41806278 - 15
A Case Report of Tolvaptan Therapy for ADPKD Patients With COVID-19. The Need for Appropriate Counselling for Temporary Drug Discontinuation.
Capelli I, Iacovella F, Ghedini L, et al.
In vivo (Athens, Greece) 2022; (36(4)):1994-1997 doi:10.21873/invivo.12924.
PMID: 35738624
This page explains fluid intake and tolvaptan safety in ADPKD for educational purposes and does not replace medical advice. Ask your nephrologist for a fluid plan based on your kidney function, heart health, sodium level, and medicines.
Get notified when new evidence is published on Autosomal dominant polycystic kidney disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.